Genelux (GNLX) Revenue & Revenue Breakdown
Genelux Revenue Highlights
Latest Revenue (Y)
$170.00K
Genelux Revenue by Period
Genelux Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $170.00K | -98.46% |
2022-12-31 | $11.07M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Genelux Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | -100.00% |
2024-03-31 | $8.00K | -99.45% |
2023-12-31 | $1.46M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | -100.00% |
2023-03-31 | $170.00K | 150.00% |
2022-12-31 | $68.00K | -99.38% |
2022-09-30 | $11.00M | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Genelux Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
IVA | Inventiva | $17.50M | $15.58M |
NAMS | NewAmsterdam Pharma Company | $14.09M | $2.13M |
IKNA | Ikena Oncology | $9.16M | - |
CNTA | Centessa Pharmaceuticals | $6.88M | - |
DYAI | Dyadic | $2.90M | $1.96M |
GNLX | Genelux | $170.00K | - |
CGEM | Cullinan Oncology | - | - |
IMRX | Immuneering | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
CING | Cingulate | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
TERN | Terns Pharmaceuticals | - | - |
CELC | Celcuity | - | - |
LRMR | Larimar Therapeutics | - | - |
MNPR | Monopar Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
CMPX | Compass Therapeutics | - | - |
MLTX | MoonLake Immunotherapeutics | - | - |